Skip to main content

Validation of RRx-001 as a Novel Disease-modifying Therapeutic for Parkinson's Disease

Study Rationale: Our project will test the effectiveness of a new treatment for Parkinson’s disease (PD) called RRx-001. We believe this drug could be beneficial in PD by blocking inflammasome activation which drives inflammation and has been linked to the PD progression.

Hypothesis: We propose that RRx-001 could be a safe and effective treatment for Parkinson’s disease based on our results in animal models and our ongoing clinical trials with this drug in other diseases.

Study Design: We will test the effectiveness of RRx-001 in multiple pre-clinical models of Parkinson’s disease and also in cell culture studies. We will determine if RRx-001 could prevent or rescue Parkinson’s pathology in these models, indicating that this drug could have potential to be tested in people with Parkinson’s.

Impact on Diagnosis/Treatment of Parkinson’s disease: There are currently no treatments for PD. Our drug has been shown to be safe and well-tolerated in human clinical trials date with no major adverse events reported. Therefore, if our testing of RRx-001 in PD models is successful in our project, it can directly enter clinical trials for PD as a new treatment.

Next Steps for Development: If results of our testing in pre-clinical models are positive, we will seek additional funding to progress this drug into Phase 2 clinical trials for Parkinson’s disease to determine if it could be a new means by which to slow or halt the progression of PD.


  • Tony R. Reid, MD, PhD

    La Jolla, CA United States

  • Richard Gordon, PhD, DABT

    Brisbane QLD Australia

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.